Name | CWP232228 |
Description | CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting the growth of breast cancer and liver cancer stem cells (CSC) without toxicity. |
In vitro | CWP232228 (0.01-100 μM; 48 hours) inhibited cell proliferation, with IC50 values of 2 μM in mouse (4T1) and 0.8 μM in human (MDA-MB-435) breast cancer cell lines. In Hep3B, Huh7, and HepG2 cells, CWP232228 (0.01-10 μM; 48 hours) demonstrated IC50 values of 2.566, 2.630, and 2.596 μM, respectively. |
In vivo | CWP232228 (100 mg/kg, administered i.p.; daily; mice with 4T1 cell tumors for 21 days; mice with MDA-MB-435 cell tumors for 60 days) significantly reduced tumor volume. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 60.00 mg/mL (83.61 mM), Sonication is recommended.
|
Keywords | β-catenin | Wnt | stem | signaling | liver | Inhibitor | inhibit | CWP-232228 | CWP232228 | CWP 232228 | cells | Cancer | Breast | Beta catenin |
Inhibitors Related | PRI-724 | Wnt pathway activator 1 | TNIK-IN-3 | MSAB | EMT inhibitor-1 | FzM1 | CHIR-99021 | XAV-939 | HLY78 | TNIK-IN-2 | Nefopam hydrochloride | KY-05009 |
Related Compound Libraries | Osteogenesis Compound Library | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Hematonosis Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Active Compound Library | Neuronal Differentiation Compound Library |